| 9.38 -0.41 (-4.19%) | 12-31 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.03 | 1-year : | 14.05 |
| Resists | First : | 10.3 | Second : | 12.03 |
| Pivot price | 9.48  |
|||
| Supports | First : | 9.01 | Second : | 8.21 |
| MAs | MA(5) : | 9.66 |
MA(20) : | 9.53 |
| MA(100) : | 7.1 |
MA(250) : | 0 | |
| MACD | MACD : | 0.3 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 71.9 |
D(3) : | 72.2 |
| RSI | RSI(14): 53 |
|||
| 52-week | High : | 10.3 | Low : | 2.59 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ DSGN ] has closed above bottom band by 41.3%. Bollinger Bands are 34.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.89 - 9.95 | 9.95 - 9.99 |
| Low: | 9.09 - 9.16 | 9.16 - 9.21 |
| Close: | 9.28 - 9.39 | 9.39 - 9.47 |
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
Wed, 31 Dec 2025
Design Therapeutics (NASDAQ:DSGN) Shares Down 4.5% - What's Next? - MarketBeat
Wed, 17 Dec 2025
Design Therapeutics (NASDAQ:DSGN) Shares Down 4.5% - Should You Sell? - MarketBeat
Sat, 06 Dec 2025
Design Therapeutics (DSGN) Price Target Increased by 41.00% to 11.98 - Nasdaq
Wed, 03 Dec 2025
Leerink Partners Upgrades Design Therapeutics (DSGN) - Nasdaq
Wed, 03 Dec 2025
Design Therapeutics Shares Rise After Leerink Upgrade - marketscreener.com
Wed, 26 Nov 2025
Design Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 57 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 35.9 (%) |
| Held by Institutions | 58.9 (%) |
| Shares Short | 2,110 (K) |
| Shares Short P.Month | 1,850 (K) |
| EPS | -1.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.5 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -20.5 % |
| Return on Equity (ttm) | -29.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.02 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.36 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -52 (M) |
| Levered Free Cash Flow | -30 (M) |
| PE Ratio | -7.89 |
| PEG Ratio | 0 |
| Price to Book value | 2.67 |
| Price to Sales | 0 |
| Price to Cash Flow | -10.23 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|